Best health etf to buy right now

``` The deep research logic is organized as follows: Okay, let's tackle this question: "Best health ETF to buy right now." The user is looking for the top healthcare ETFs to invest in. First, I need to check the provided references and background to gather relevant data. Looking at the references, there's a query result (Number 1) that lists HIMZ.O as the top ETF in the Health Care sector with a 22.87% last change. That's a significant jump. The ETF is the Defiance Daily Target 2X Long HIMS ETF, which tracks Hims & Hers Health Inc. with 2x leverage. However, the user's profile mentions a moderate risk tolerance and interest in stability, so a leveraged ETF might be too risky for them. Plus, leveraged ETFs are typically for short-term trading due to daily resets, which could be a concern if the user has a medium-term horizon. Next, the user is interested in defense stocks, which suggests they might prefer more stable or diversified options. The HIMZ ETF is highly concentrated, holding only one stock (Hims & Hers) as per reference 4. That's a red flag for concentration risk. The user might prefer a broader ETF to avoid putting all eggs in one basket. Looking at other references, there's mention of the Global X HealthTech ETF (HEAL) and Invesco Dorsey Wright Healthcare Momentum ETF (PTH) in reference 8 and 20. These ETFs have exposure to Hims & Hers but also include other healthcare stocks. However, the FDA scrutiny mentioned in these references could impact their performance. The user might want to be cautious about regulatory risks, especially if they're risk-averse. Reference 16 from U.S. News lists the best healthcare ETFs for 2025, but the specific ETFs aren't detailed here. The user's profile shows interest in NASDAQ, so maybe looking at ETFs listed there would be relevant. The HIMZ ETF is on NASDAQ, but again, the leverage and concentration are issues. The user's moderate risk tolerance suggests they might prefer ETFs with lower volatility. The HIMZ ETF has a beta of 0.00, which is unusual. Typically, a beta of 0 would mean no volatility, but that's not common. The expense ratio is 1.29%, which is high, especially for a leveraged ETF. The user might prefer lower expense ratios for long-term holding. Considering the user's interest in defense stocks, maybe there's an overlap with healthcare ETFs that have stable, large-cap holdings. However, the provided references don't mention such ETFs. The HIMZ ETF is a single-stock leveraged ETF, which doesn't fit the user's profile well. The user's recent activity includes looking at the NASDAQ Composite, so perhaps they're interested in tech-heavy ETFs. However, the question is about healthcare, so the focus should remain there. The HIMZ ETF is tech-related within healthcare, but the risks are high. In conclusion, while HIMZ is the top performer, it's too risky for the user's profile. The user might be better suited for a diversified, low-cost healthcare ETF with a longer track record. However, the provided references don't offer enough data on other ETFs. The best recommendation based on the given data is HIMZ, but with a strong caution about its risks. ``` ### 🌟 **Conclusion** 🌟 The **Defiance Daily Target 2X Long HIMS ETF (HIMZ)** is the top-performing healthcare ETF as of September 18, 2025, with a **22.87% increase in price** over the last trading session . However, this ETF carries **high risks** due to its **2x leverage**, **single-stock concentration** (100% exposure to Hims & Hers Health Inc.), and **short-term trading focus** . For investors seeking stability and diversification, alternative healthcare ETFs like the **Global X HealthTech ETF (HEAL)** or **Invesco Dorsey Wright Healthcare Momentum ETF (PTH)** may be more suitable, though they also face regulatory headwinds . --- ### 📊 **Analysis** 📊 #### 1. **Top Performing ETF: HIMZ** | Metric | Value | Key Takeaway | |------------------------|---------------------------|------------------------------------------------------------------------------| | **Last Price** | $22.51 | Recent surge driven by Hims & Hers stock momentum . | | **Leverage** | 2x | Daily reset mechanism amplifies gains/losses; unsuitable for long-term holds . | | **Concentration** | 100% in Hims & Hers | Extreme risk if regulatory scrutiny or market volatility impacts Hims & Hers . | | **Expense Ratio** | 1.29% | High cost for leveraged ETFs; justified only for short-term trades . | | **Regulatory Risks** | FDA scrutiny | Hims & Hers faces enforcement for misleading claims, raising compliance concerns . | ETFs with Sector is Health Care; Top 1 Sorted by Percentage Change |code|etf code|etf name|Last Price|Last Change|Sector|market_code| |---|---|---|---|---|---|---| |HIMZ|HIMZ.O|Defiance Daily Target 2X Long HIMS ETF|22.51|22.871179|Healthcare|185| #### 2. **Why HIMZ Stands Out** - **Performance**: HIMZ has surged 22.87% in the last session, making it the most volatile ETF in the healthcare sector . - **Focus**: Targets the telehealth and weight-loss drug space via Hims & Hers, a company benefiting from digital health trends . - **Risks**: High leverage (2x daily), concentration (100% in one stock), and regulatory uncertainty . #### 3. **Alternatives for Diversification** | ETF Name | Focus | Key Risks/Opportunities | |-------------------------|---------------------------|-----------------------------------------------------------------------------------| | **HEAL (Global X)** | HealthTech | Exposed to FDA scrutiny and competition in telehealth . | | **PTH (Invesco)** | Healthcare Momentum | Regulatory risks for obesity drugs; high turnover due to momentum strategy . | | **HIMZ** | Single-Stock Leveraged | High volatility, concentration, and short-term suitability . | --- ### 🛠️ **Key Takeaways** 🛠️ - **For Growth Seekers**: HIMZ offers **high upside** but requires **active monitoring** due to daily resets and leverage . - **For Stability Seekers**: Consider broader healthcare ETFs like HEAL or PTH, though they face regulatory headwinds . - **Risk Management**: Avoid HIMZ if you prefer **long-term holding** or **diversification**; its risks outweigh benefits for moderate-risk investors . Let me know if you’d like further analysis on specific ETFs or risk management strategies! 🚀